Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | TSHR | P16473 | 3/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4487837 | 0.86 | KMT2A (0.60) | LMNATSHRSMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL24113581 | 0.82 | LMNA (0.71) | LMNATSHRSMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL24113580 | 0.82 | SMN1; SMN2 (0.92) | LMNATSHRSMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL24113363 | 0.82 | LMNA (0.71) | LMNATSHRSMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL6675241 | 0.82 | LMNA (0.74) | LMNATSHRSMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL28047331 | 0.79 | KMT2A (0.65) | KMT2AMEN1ALDH1A1TP53POLB | |
| SCHEMBL28047359 | 0.79 | KMT2A (0.65) | SMN1; SMN2KMT2AALDH1A1TP53POLB | |
| SCHEMBL4668947 | 0.79 | DPP4 (0.81) | CYP3A4DPP4 | |
| SCHEMBL4668943 | 0.79 | DPP4 (0.81) | CYP3A4DPP4 | |
| SCHEMBL555383 | 0.79 | DPP4 (0.61) | LMNATSHRSMN1; SMN2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1404675-B1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK AS (DK) | 2008-03-12 | — | — | EP | disclosed |
| US-7192952-B2 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK, A/S (DK) | 2007-03-20 | — | — | US | disclosed |
| US-20050148606-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | KANSTRUP ANDERS B (DK) | 2005-07-07 | — | — | US | disclosed |
| US-6869947-B2 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | disclosed |
| EP-1463727-A2 | HETEROCYCLIC COMPOUNDS THAT ARE INHIBITORS OF THE ENZYME DPP-IV | NOVO NORDISK A/S (DK) | 2004-10-06 | — | — | EP | disclosed |
| WO-2004033455-A2 | HEMISUCCINATE SALTS OF HETEROCYCLIC DPP-IV INHIBITORS | NOVO NORDISK A/S (DK) | 2004-04-22 | — | — | WO | disclosed |
| EP-1404675-A1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2004-04-07 | — | — | EP | disclosed |
| US-20030199528-A1 | Hetrocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2003-10-23 | — | — | US | disclosed |
| US-20030105077-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | US | disclosed |
| WO-2003024965-A2 | HETEROCYCLIC COMPOUNDS THAT ARE INHIBITORS OF THE ENZYME DPP-IV | NOVO NORDISK A/S (DK) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003004496-A1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199528-A1 | Hetrocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP3 | LMNA 3568/4885TSHR 4395/4885SMN1; SMN2 4233/4885 |
| US-20050148606-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP3 | LMNA 4238/4885TSHR 3409/4885SMN1; SMN2 3620/4885 |
| US-20030105077-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP3 | LMNA 4341/4885TSHR 3634/4885SMN1; SMN2 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.